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As melanoma survival rates continue to increase, optimal surveillance strategies for recurrences are needed, as are eﬀective
imaging modalities. Therefore, we performed a meta-analysis to evaluate the current state of imaging modalities for surveillance
of melanoma in the published medical literature to determine the sensitivity, speciﬁcity, and positive predictive values of
ultrasonography, computed tomography (CT), positron emission tomography (PET), and CT-PET combined. Ultrasonography
was found to be the most sensitive and speciﬁc for detecting lymph node metastases, and PET-CT was the most sensitive and
speciﬁc for detecting distant metastases. In addition to identifying appropriate surveillance methods, future studies should focus
on the most eﬀective and cost-eﬀective intervals for performing these tests. In addition, the results from the meta-analysis related
to sensitivity and speciﬁcity of the tests should be made available to doctors in community practice.
1.Introduction
The number of melanoma survivors in the United States
continues to increase, largely because of the successful treat-
ment of newly diagnosed, early-stage disease [1]. However,
upto50%ofthesepatientsareatriskforrecurrence,whichis
mostcommonintheyearsimmediatelyafterdiagnosis[2–7].
An estimated 20% of all ﬁrst recurrences occur locally, 50%
occur in the regional lymph nodes, and 30% arise at distant
sites [8]. Despite the known beneﬁts of early detection of
recurrence, no evidence-based surveillance guidelines exist
and clinical patterns vary widely [8]. Thus, it is important
to deﬁne optimal follow-up strategies, including the most
eﬀective tests and evaluation intervals.
The increased number of melanoma survivors poses
several potential clinical issues. First, as more cancer patients
survive, doctors have an obligation to provide eﬀective post-
treatment surveillance as well as evaluate and treat new pa-
tients [9–12]. Second, it has been estimated that as many
as 72% of melanoma patients detect their own recurrences;
thus, it may be argued that patients provide adequate sur-
veillance on their own [13]. However, this estimate may be
ﬂawed as studies have not determined whether these recur-
rences were directly or indirectly detected (direct measures
are those in which patients primarily detect their own re-
currence; indirect measures are those in which a patient ini-
tiates followup with a physician, who subsequently detects
the recurrence) [14]. In addition, the actual rate of patient-
detected recurrences is unclear because multiple strategies
have been used to evaluate recurrence detection [14].
Despite advances in imaging technology, most recur-
rences are detected on clinical examination by the patient or
physician [13]. Whether there is a survival beneﬁt from early
detection of metastases is controversial because patients with
disseminated disease have historically had limited treatment
options [14]. Assuming that early detection of melanoma
metastases results is beneﬁcial, identifying the most eﬀective
contemporary diagnostic imaging modalities is crucial. We
recently performed a meta-analysis of the published medical
literature [15] using statistical Bayesian bivariate binomial
models to combine the data [16].
2. Methods
Patient-level data was extracted from published studies
which used ultrasonography, computed tomography (CT),
positron emission tomography (PET), and CT and PET2 Dermatology Research and Practice
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Figure 1: Meta-analysis selection process.
combined (CT-PET) to detect regional lymph nodes and
distant metastases in melanoma patients. The eligibility cri-
terion for study inclusion was a minimum of 6 months of
posttreatment followup to provide an opportunity for ad-
ditional imaging or clinical information to determine the
accuracy and precision of these imaging modalities. Imaging
results were classiﬁed as true positive, true negative, false
negative, or false positive using primarily histologic analyses
of suspicious sites (lymph node specimens or distant metas-
tases) or clinical outcomes after a minimum of 6 months of
postdiagnosis surveillance. A 14-item Quality Assessment of
Diagnostic Accuracy Studies (QUADAS) scale was used to
evaluate each study to determine potential sources of bias
within each of the articles included in the meta-analysis [17].
In addition to sensitivity and speciﬁcity, the diagnostic
odds ratio (calculated as the (TP/FN)/(FP/TN)) was also
used as an indicator of test performance. The 95% credible
intervals (CrI), which are used in Bayesian statistics for
interval estimation, were calculated for each test estimate.
Bayesian models were used for the meta-analysis because
they can be applied to both large and small studies without
ad hoc correction [16]. The positive predictive value for
each imaging modality was also calculated for patients with
estimated low (5%), intermediate (15%), and high (30%)
risks of recurrence.
3. Results and Discussion
We identiﬁed 74 studies that evaluated the utility of ultra-
sonography, CT, PET, and CT-PET (Figure 1) for the de-
tection of melanoma recurrence. These studies included data
from 10,528 melanoma patients, whose data were extracted
and used to create two-by-two tables. The mean overall
QUAdAS score for all of the studies was 5.8, with a standard
deviation of 2.5, indicating that most of the studies were of
only fair quality but satisﬁed the needs for this assessment.
Among the four imaging modalities, ultrasonography
hadthehighestsensitivity,96%(95%CrI:85–99);speciﬁcity,
99% (95% CrI: 95–100); diagnostic odds ratio, 1675 (95%
CrI: 226.6–15920) for lymph node metastasis surveillance
compared with CT, PET, and PET-CT (Table 1). Similarly,
ultrasonography had the highest positive predictive value,
83% (95% CrI = 36–100), for the detection of lymph node
metastasis. For the surveillance of distant melanoma metas-
tasis, PET-CT had the highest sensitivity, 86% (95% CrI: 76–
93) and diagnostic odds ratio, 67 (95% CrI: 76–93).
The results of this meta-analysis indicate that the ana-
tomic site to be evaluated should be considered when choos-
ing an imaging modality. Of the four diagnostic imaging
modalitiesevaluated,ultrasonographywasthemostsensitive
and speciﬁc and had the highest positive predictive value
for lymph node assessment. PET-CT was the most sensitiveDermatology Research and Practice 3
Table 1: Surveillance of melanoma patients (adapted from Xing et al. [15]).
Surveillance imaging modality ﬁndings
Method Sensitivity Speciﬁcity Diagnostic odds ratio
Ultrasound 96% (85%–99%) 99% (95%–100%) 1675 (226.6–15920)
CT scan 61% (15%–93%) 97% (70%–100%) 46.25 (2.27–1354)
PET scan 87% (67%–96%) 98% (93%–100%) 391 (68–2737)
CT-PET scan 65% (20%–93%) 99% (92%–100%) 196 (10.77–4675)
and speciﬁc and had the highest positive predictive value for
distant metastasis surveillance, but it also had the highest
number of false positives, resulting in lower speciﬁcity and
loss of precision. Furthermore, for patients at low risk of
metastasis, the low positive predictive value of PET-CT at
33% (95% CrI: 9–61) suggests that its routine use is not
warranted in this scenario without additional clinical indi-
cations.
The meta-analysis included all eligible studies from 1990
to 2009 with data on contemporary imaging modalities used
for the surveillance of melanoma survivors. The literature
search was performed using MEDLINE (from January 1,
1990, through June 30, 2009), Cancerlit (from January 1,
1990, through October 31, 2002), and the Controlled Trials
Register from the Cochrane Library (from January 1, 1990,
through June 30, 2009) and key words: “melanoma”; “lymph
node metastasis”; “ultrasound”; “computed tomography”;
“positron-emission tomography”; “positron emission tomo-
graphy with computerized tomography.” Publications were
onlyeligibleiftheywereinEnglish.Anadditionalstrengthof
the analysis is the Bayesian model which was applied in order
to appropriately integrate heterogeneous data from both
large and small studies [18]. Limitations of the meta-analysis
include the advancement of diagnostic imaging technology
over the past ten years as well as potential selection bias of
studies included. Laboratory assessment has also been used
forsurveillanceofmelanomarecurrencesbutwasnotinclud-
ed in the meta-analysis; however, no prospective studies exist
to support its use [1].Suchassessmentsmaynotbenecessary
for eﬀective postdiagnosis surveillance.
It is widely acknowledged that no evidence-based strate-
gies exist for most cancers, including melanoma [19]. As the
number of cancer survivors and the availability of contem-
porary medical technologies increase, so does the cost of sur-
vivorship care [14] .O v e rad e c a d ea g o ,B r o b e i le ta l .[ 20]r e -
ported that recurrence screening in melanoma survivors
accounted for an estimated 80% of care costs which could
total $27 to $32 million to provide eﬀective surveillance to all
patients over a 20-year period.
Creating eﬀective and cost-eﬀective clinical practice
guidelines for posttreatment cancer surveillance is critical.
Such guidelines, if evidence based, may be useful for meas-
uring quality of care in diﬀerent settings [21–29].
The next step in evaluating the evidence for melanoma
practice guidelines is to evaluate the appropriate intervals for
followup in patients at varying risk of recurrence [30]. While
the gold standard for such an evaluation is a randomized
controlledstudy,suchstudieswithmultiplecomparisonsand
long follow-up intervals are diﬃcult to conduct. Melanoma
surveillance recommendations should consider type of eval-
uation (examination with or without diagnostic imaging),
frequency, and duration. In their research, Brobeil et al. [20]
found that an intensive follow-up program led to a high-
er detection rate of melanoma in situ (noninvasive stage I
melanomas) and a lower detection rate of invasive mela-
nomas, indicating that frequent follow-up examinations
may be beneﬁcial. However, the investigators acknowledged
that their recommendations were not particularly cost ef-
fective, which may lead to decreased implementation across
the medical community. Other studies have reported that
intense, frequent followups serve only to increase patient
anxiety [14]. Thus, it is important to ﬁnd a balance between
intense follow-up schedules and minimal schedules, which
may result in early-stage recurrences going undetected.
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